- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 16/08 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus
Détention brevets de la classe C07K 16/08
Brevets de cette classe: 1405
Historique des publications depuis 10 ans
|
77
|
106
|
92
|
100
|
119
|
106
|
115
|
105
|
85
|
40
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 4786 |
28 |
| Novartis AG | 10173 |
22 |
| City of Hope | 1041 |
20 |
| The Regents of the University of California | 20815 |
18 |
| Genentech, Inc. | 4114 |
18 |
| Duke University | 3181 |
16 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3010 |
16 |
| Humabs Biomed SA | 120 |
14 |
| The University of North Carolina at Chapel Hill | 2114 |
14 |
| The Rockefeller University | 583 |
12 |
| Vanderbilt University | 2028 |
12 |
| VIR Biotechnology, Inc. | 152 |
12 |
| Xencor, Inc. | 411 |
12 |
| Xiamen University | 583 |
12 |
| Deutsches Krebsforschungszentrum | 397 |
11 |
| Icahn School of Medicine at Mount Sinai | 1045 |
11 |
| Yang Sheng Tang Company Limited | 55 |
10 |
| Institute for Research in Biomedicine | 99 |
9 |
| F. Hoffmann-La Roche AG | 7808 |
8 |
| Glaxosmithkline Biologicals S.A. | 1603 |
8 |
| Autres propriétaires | 1122 |